EpiCept Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported, net loss attributable to common stockholders was $4.8 million, or $0.04 per share on revenue of $0.12 million compared with a net loss attributable to common stockholders of $6.2 million, or $0.09 per share on revenue of $0.08 million for the third quarter of 2008. Loss from operations was $5.02 million compared to $5.36 million for the same period a year ago. Net loss before income taxes was $4.81 million compared to $6.16 million for the same period a year ago. For the nine months, the net loss attributable to common stockholders was $34.4 million, or $0.30 per share on revenue of $0.32 million, compared with a net loss attributable to common stockholders of $20.0 million, or $0.36 per share on revenue of $0.17 million for the nine months ended September 30, 2008. Net cash used in operating activities was $25.7 million, compared with $11.9 million for the first nine months of 2008. Loss from operations was $14.55 million compared to $16.89 million for the same period a year ago. Net loss before income taxes was $34.37 million compared to $20.00 million for the same period a year ago.

EpiCept Corporation announced that Health Canada has accepted for review the company's New Drug Submission (NDS) for Ceplene(R) (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. Health Canada's performance target for the completion of review and a decision is within 300 days. EpiCept also announced that Israel's Ministry of Health has accepted a marketing application for Ceplene(R) for the remission maintenance of AML patients in first remission. The company's distribution and marketing partner for Ceplene(R) in Israel, Megapharm Ltd., filed the application and will market Ceplene(R) upon approval. A decision on this application is anticipated late next year.

EpiCept Corporation announced that it has appointed Bernard R. Tyrrell as the company's Senior Vice President, Sales and Marketing, a newly created position. Mr. Tyrrell joins EpiCept with a wealth of experience in pharmaceutical marketing and business development, both in the U.S. and internationally. Most recently, he led the Oncology Division of Otsuka America Pharmaceutical Inc. While at Otsuka America, Mr. Tyrrell was among those responsible for developing a world-class oncology division in North America and drove early brand accomplishments.